Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan prophylaxis to reduce lipase and amylase elevation after ERCP
2005-004545-34Phase 3Completed
- Sponsor
- Unit of Esophageal and Gastric Research (Karolinska Institutet)
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of losartan in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) and acute pancreatitis (AP), sponsored by Unit of Esophageal and Gastric Research (Karolinska Institutet). Primary endpoints: Change in serum lipase levels after ERCP and Change in serum amylase levels after ERCP. Started Jan 2006; status: completed.
02
Drugs
losartan
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)acute pancreatitis (AP)
Beyond the preview
Go deeper on 2005-004545-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004545-34.